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INTRODUCTION
Hilar cholangiocarcinoma (HCCA) is the most common 
type of bile duct cancer, accounting for 46% to 97% of all bile 
duct cancers.1,2 Surgical resection is only possible in 20% to 
30% of patients with HCCA. Therefore, palliative bile drainage 
intervention is required for patients with unresectable HCCA. 
The three established methods used for palliation of HCCA 
are endoscopic drainage, percutaneous drainage, and surgical 
bypass. However, there is a lack of well-designed comparative 
or randomized studies regarding the optimal method. Al-
though the Asia-Pacific Working Group on Hepatobiliary Can-
cer recently made several recommendations,1 establishing a 
consensus regarding palliation of HCCA remains a challenge. 
In this review, we describe several points of concern for bili-
ary drainage in HCCA based on evidence and personal experi-
ence, and discuss the palliative drainage methods for advanced 
HCCA, mostly for patients with higher than Bismuth type 
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III HCCA.
HOW MUCH OF THE LIVER SHOULD BE 
DRAINED IN A PATIENT WITH HCCA 
AND IS MULTISECTORIAL DRAINAGE 
NECESSARY?
The right, left, and caudate lobes of the liver occupy approxi-
mately 55% to 60%, 30% to 35%, and 10% of the liver volume, 
respectively.3 One study showed that only 25% of the liver vol-
ume can be drained for palliation of jaundice not accompanied 
by cholangitis.4 However, another study reported a greater de-
crease in bilirubin level, lower incidence of early cholangitis, 
and longer patient survival when >50% of the liver volume was 
drained, compared to draining <50%.5 The Asia-Pacific Work-
ing Group on Hepatobiliary Cancer also recommends draining 
>50% of the liver volume.1
A close relationship between drained liver volume and the 
number of stents has been identified. Increased bilateral, rath-
er than unilateral, stenting is required to increase drained liver 
volume. A single stent alone can drain both lobes in a patient 
with Bismuth type I HCCA, but draining patients with Bis-
muth types II to IV requires multiple stents. Unilateral stenting 
has a high technical success rate for stent placement and low 
early complication rates.6 However, there is a limitation on suf-
ficient drainage >50% of liver volume for patients with Bis-
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technically achievable with appropriate endoscopic expertise, 
development of metal stents, and higher technical and func-
tional success rates, even in patients with Bismuth types III or 
IV.21-29 Thus, the number of biliary stents inserted for pallia-
tion and drained liver segments in patients with HCCA must 
be determined based on the extent of malignant biliary stric-
tures observed on pre-procedural imaging and the degree of bili-
ary tract contamination during biliary drainage. 
SELF-EXPANDING METAL STENTS ARE 
BETTER THAN PLASTIC STENTS FOR 
ADVANCED HCCA
The types of stents used for palliation in HCCA include 
plastic stents (PSs) and uncovered self-expanding metal stents 
(SEMSs). PS are less expensive and their insertion and removal 
are technically easier compared to SEMS. However, because 
the diameter of PS is smaller than that of SEMS (10 to 12 Fr vs. 
8 to 10 mm, respectively), PS occlude more rapidly than SEMS 
and has a shorter median patency time (1.4 to 3 months vs. 6 
to 10 months, respectively).30 Moreover, insertion of more than 
muth type II and higher. Additionally, if an infected bile duct 
cannot be drained, the risk of cholangitis and liver abscess may 
increase (Fig. 1). In contrast, bilateral stenting preserves func-
tional liver volume, lowers the risk of cholangitis, and reduces 
complications by draining the infected duct when there is in-
flammation in a bilateral infected duct, extending patient sur-
vival (Table 1).7-14
Injecting contrast dye into undrained ducts can increase the 
incidence of postprocedural cholangitis and lower the survival 
rate.15 Preoperative staging and procedural planning with non-
invasive imaging, such as magnetic resonance cholangiography 
(MRCP) or computed tomography (CT), are important in low-
ering the risk of cholangitis by unsuccessful endoscopy.16-20 These 
imaging techniques prevent inadvertent injection of contrast 
into atrophied or multiple unintended hepatic segments. Fur-
thermore, selectively targeted and planned drainage lowers the 
risk of cholangitis or septicemia by identifying the inflamed 
bile duct. Therefore, excluding an atrophied segment of lobe 
or segment and effectively draining the dominant liver lobe 
lowers the risk of cholangitis and extends patient survival. These 
benefits arising from bilateral drainage with metallic stents are 
A  
C
B
D
Fig. 1. Formation of a liver abscess after insertion of a unilateral metal stent in a patient with hilar cholangiocarcinoma. (A) Inoperable papil-
lary-type cholangiocarcinoma (white arrow) diagnosed as Bismuth type IV based on the initial computed tomography scan. (B) A self-expand-
able metal stent was inserted unilaterally in the left lobe via the percutaneous tract after failed endoscopic stenting. (C) The stent was occlud-
ed due to tumor in-growth after 8 months. (D) The liver abscess developed in the right lobe, the contralateral side during stent insertion. 
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two 10-Fr diameter PS is difficult and can increase migration 
rates.31,32 In contrast, SEMS used for HCCA are uncovered, al-
lowing drainage of side branches. SEMS have superior success 
rates, minimal adverse effects, fewer requirements for re-inter-
vention, and higher patient survival compared to PS.33 Despite 
the high initial cost, SEMS have superior cost-effectiveness due 
to the greater success rate, shorter hospital stay, fewer blockages, 
fewer re-interventions, and lower antibiotic needs compared 
to PS, when expected patient survival is >4 to 6 months (Table 
2).34-36 The Asia-Pacific Consensus also recommends biliary pal-
liation with SEMS for patients with predicted survival >3 months 
and Bismuth types II to IV HCCA.1 However, if biliary drain-
age is performed when a treatment plan for HCCA has not been 
definitely determined, PS can be temporarily inserted, as PS are 
removable while SEMS are not.37
INSERTION OF MULTIPLE SEMS:  
SIDE-BY-SIDE OR STENT-IN-STENT
There are two methods of insertion of multiple SEMS for 
HCCA. The “side-by-side” method requires insertion of the 
first stent in one of the hepatic ducts and insertion of the sec-
ond stent into the contralateral hepatic duct parallel to the first 
stent.9,38-40 The “stent-in-stent” method requires insertion of the 
second stent in the contralateral hepatic duct through mesh of 
the first stent.23,41-46 Insertion of a stent in bilateral side-by-
side stent placement is easier when guidewires are inserted 
into the right and left hepatic ducts. Endoscopic revision of 
the stents is also easier on stent occlusion.38 However, disad-
vantages include the potential for interference when insert-
ing the delivery system for the second stent due to resistance 
from the already inserted first stent and difficulties in align-
ing the distal ends of the two stents. A simultaneous side-by-
side deployment method using a thin 6-Fr delivery system was 
developed to overcome these issues and has shown a high suc-
cess rate.39 However, side-by-side deployment can occlude a 
portal vein and increase the rate of cholangitis because of ex-
cessive expansion of the bile duct by the parallel stents. The ex-
cessive expansion force of two deployed SEMS, particularly 
large-diameter SEMS with a closed metal mesh design, can 
cause severe pain and vascular injury, possibly leading to mas-
sive bleeding.
Effective drainage can be difficult using the side-by-side 
method in a non-dilated common bile duct and an insufficiently 
deployed stent can block bile duct flow. Bilateral stent-in-stent 
deployment is less likely to cause these complications because 
the stents overlap within the common bile duct. However, it is 
technically difficult to insert a guidewire for the second stent 
into the contralateral bile duct through the mesh of the first 
stent. Moreover, endoscopic revision for an occluded stent is dif- Ta
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ficult compared to the side-by-side method. Large open-celled 
wire mesh stents were designed to resolve these issues, using a 
guidewire to facilitate insertion of the second stent and improve 
the success rate. This mesh design enables an easy re-interven-
tion. However, the expanding radial force is reduced because of 
the large cell and susceptibility to tumor in-growth increases.
The success rates for the side-by-side and stent-in-stent 
methods are 73.3% to 100% and 80% to 100%, respective-
ly.9,38-47 Although the incidence of complications is higher for 
the side-by-side method than the stent-in-stent method, stent 
patency rates are superior.48 No well-designed large-scale 
comparative studies with long-term follow-up have been per-
formed; therefore, no definite consensus has been reached. 
Nevertheless, it is expected that attempts to improve the suc-
cess rate with modifying stents and technical developments of 
the stent-in-stent method will result in its more frequent use.
ENDOSCOPIC INSERTION OF A SEMS 
MAY NOT ALWAYS BE THE INITIAL  
APPROACH
Endoscopic palliation is a less invasive, one-step procedure 
compared to percutaneous intervention and commonly used 
as initial treatment for palliation of HCCA. However, it is es-
sential to accurately define the extent of biliary ductal involve-
ment before deciding between endoscopic or percutaneous 
methods as the initial palliative method of HCCA. A MRCP or 
CT examination may be helpful in determining the initial meth-
od depending on the Bismuth classification of HCCA. Endo-
scopic treatment is generally the preferred approach for percuta-
neous drainage for Bismuth types I and II. However, only the 
technical aspects and success rates have concerned patients 
with advanced HCCA (Bismuth type III and IV), while techni-
cal difficulties and associated complications have been neglect-
ed. Complications, such as bleeding and perforation from an 
A  
C
B
D
Fig. 2. Cholangiograms demonstrating successful palliation using the percutaneous method after failed endoscopy. (A) Magnetic resonance 
cholangiography demonstrated a Bismuth type IV hilar malignancy, with dilation of both intrahepatic ducts. (B) The guidewire was not able 
to pass through the stricture site during endoscopy due to tightness. (C) An ultrasound-guided puncture at both intrahepatic ducts was suc-
cessful. (D) Two self-expandable metal stents (X-type) were inserted successfully via the previous percutaneous tracts.
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endoscopic retrograde cholangiopancreatography for endo-
scopic drainage and the high incidence of postprocedural 
cholangitis, are a problem. A multicenter retrospective study 
found that percutaneous procedures have significantly higher 
success rates and a lower risk of cholangitis than endoscopic 
drainage in patients with advanced HCCA.49 Therefore, the 
Asian-Pacific Consensus recommends that endoscopic pallia-
tion be considered as an initial treatment for less-advanced 
Bismuth types (I and II) and that percutaneous palliation be 
considered for advanced Bismuth types (III and IV).1 How-
ever, endoscopy is the initial approach, even in patients with 
advanced Bismuth types in actual clinical practices at many in-
stitutes, including ours. Nevertheless, we prefer to convert en-
doscopy to a percutaneous approach when any difficulties are 
encountered during the procedure. This policy is better than a 
“never give up policy” for patient safety and preventing pro-
cedure-related adverse events. Unlike previous studies describ-
ing only short-term outcomes, large-scale randomized studies 
are needed to investigate long-term outcomes regarding the 
duration of efficient drainage and the possibility of effective re-
intervention when a stent becomes obstructed.
WHEN SHOULD WE CALL AN  
INTERVENTIONAL RADIOLOGIST?
Drainage is necessary because the complication rate, includ-
ing postprocedural cholangitis, increases when contrast dye is 
injected into undrained bile ducts.34 Therefore, percutaneous 
drainage must be performed immediately after unsuccessful 
endoscopic drainage to prevent postprocedural cholangitis and 
improve the palliative success rate.49 The success rate of pallia-
tion is higher in a percutaneous approach in patients with ad-
vanced HCCA (Bismuth types III and IV) compared to an 
endoscopic approach. This is due to: (1) puncture at a pre-
cisely selected bile duct; (2) easier guidewire and catheter ap-
proach; and (3) a greater variety of designs for drainage (T- 
or X-shaped).50 Our comparative study of patients who 
underwent successful initial endoscopic SEMS stenting (group 
I) and patients who underwent unsuccessful initial endoscopic 
SEMS stenting but successful subsequent percutaneous SEMS 
A  
C
B
D
Fig. 3. Cholangiograms demonstrating successful palliation using the percutaneous method after failed endoscopy. (A) Magnetic resonance 
cholangiography demonstrated a Bismuth type IV hilar malignancy, with dilation of both intrahepatic ducts. (B) Although the guidewire was 
able to pass through the stricture site, the 8-Fr metal stent delivery system could not be passed during endoscopy due to tightness. (C) An 
ultrasound-guided puncture in the right intrahepatic duct was successful. (D) Two self-expandable metal stents (T-type) were inserted suc-
cessfully via the previous percutaneous tract.
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stenting (group II) showed that the success rate of endoscop-
ic stenting for patients with advanced HCCA (Bismuth types 
III and IV) was lower than that for percutaneous stenting 
(72.4% vs. 100%, respectively; p<0.05, unpublished data). 
Importantly, sequential stenting by the percutaneous method 
was possible for all patients who failed in the endoscopic ret-
rograde method through endoscopic retrograde cholangiopan-
creatography. Although strictures in these patients were tight 
and had a long segment preventing the guidewire from being 
passed in the endoscopic method, the percutaneous antero-
grade method may overcome these limitations (Figs. 2, 3). 
These results are similar to previous studies.49 Therefore, the 
percutaneous approach should be considered as initial pallia-
tion for some patients with advanced and difficult Bismuth 
types III and IV HCCA. Moreover, sequential percutaneous 
intervention is important for successful palliation when an 
endoscopic approach fails. 
CONCLUSIONS
The top priority for palliation of unresectable HCCA is to 
determine a drainage plan prior to the procedure using non-
invasive imaging, such as MRCP or CT. Moreover, it is impor-
tant to consider several factors, such as the patient’s bile duct, 
hepatic anatomical information, the patient’s condition, exist-
ing medical sources, and the endoscopist’s expertise, when se-
lecting the appropriate bile duct for drainage, type and number 
of stents, and drainage method for the most effective pallia-
tion. All attempts must be made to drain the infected bile duct, 
and a percutaneous method should be considered first for pa-
tients with advanced HCCA (Bismuth types III and IV). In 
particular, if the intention to treat initially fails using endosco-
py, it is essential to switch immediately to a percutaneous 
method.
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